Журнал неврологии и нейрофизиологии

Short Review of Current Research on the Development of Hypoestoxide as a Therapeutic Agent for Parkinsons Disease

Emmanuel A Ojo-Amaize and Howard B Cottam

Parkinson’s disease (PD) is a common neurodegenerative disorder belonging to a heterogeneous group of disorders with α-synuclein pathology and PD dementia. Hypoestoxide is being developed to combat microgliosis, astrogliosis, loss of dopaminergic neurons, motor behavioral deficits and α-synuclein pathology in PD.